Trial Information - Phase III
Phase III, 2 Arm, Randomized, Open Label, Multicenter, Registrational Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo (+/- Endocrine Therapy) After Induction Chemotherapy (Phesgo+Taxane) In Patients With Previously Untreated Her2-Positive, Estrogen Receptor Positive Locally Advanced Or Metastatic Breast Cancer
Disease Specifics: m(HER2+)
Protocol ID: WO43571
Sponsor: Roche Laboratories, Inc.
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
